Thoratec Corporation

Skip to content

Overview

Webcast ImageWebcast
Q2 2014 Thoratec Corporation Earnings Conference Call (Live)
08/06/14 at 1:30 p.m. PT
THOR (Common Stock)
Price32.13Change- 0.42
Volume325,245% Change1.29%
07/25/2014 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
07/21/14Thoratec Schedules Second Quarter Conference Call, Webcast
PLEASANTON, Calif., July 21, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the second quarter of fiscal year 2014 on Wednesday, August 6. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (... 
Printer Friendly Version
07/02/14Thoratec Acquires Apica Cardiovascular
PLEASANTON, Calif., July 2, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has acquired Apica Cardiovascular Limited ("Apica") for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million.  As part of the agreement, the Apica team based at facilities in Ireland and the United States will transition... 
Printer Friendly Version
06/27/14Thoratec Announces First HeartMate III™ Human Implant And Start Of CE Mark Trial
PLEASANTON, Calif., June 27, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE Mark Clinical Trial for HeartMate III™ commenced with the first patient implanted with this new device. "We are pleased to reach this significant clinical milestone with an important pipeline product," said Gary F. Burbach, President and Chief Executive Officer.  "We a... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.